Clinical Trials · NCT07046819
Tirzepatide in MetALD
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Enrollment
- 120
- Start date
- Jun 2026
- Locations
- 1 site, United States
- Primary endpoint
- Metabolic improvement from baseline as measured by percentage reduction of body weight and reduction in liver steatosis from baseline as measured by percentage reduction in Fibroscan controlled attenuation parameter (CAP) score.